Avalglucosidase alfa

Therapetic Avalglucosidase alfa enzyme from the original Nexviadyme® commercial drug.

Reference Standard as Aliquots

Nexviadyme®
Filters Sort results
Reset Apply
Product batch
Expiry date
Brand & Origin
Price
1. Select quantity range
2. Your quantity
05/2026
Nexviadyme®
DE
1.099,00  /mg
Select quantity:
Max: 18
Min: 1
Step: 1
Max: 18
Min: 1
Step: 1
mg

Biosimilars as Aliquots​

Filters Sort results
Reset Apply
No results found. Clear filters and try again?

Batch specific analytical data available

Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API). ​

Request an individual offer​

+ download a free sample​

1. Choose your(s) method(s) of interest
2. Provide your contact details
3. Send us your request and download a free sample report


Please provide your contact information


send us your inquiry and download a free sample file


Product Information

Here you will find the product information for the reference product.

Nexviadyme® / Avalglucosidase alfa Reference Product

Drug nameNexviadyme®
INNAvalglucosidase alfa
API typeEnzyme
Pharmacotherapeutic group
Not assigned yet
ATC code
Not assigned yet
Target of antibody
Lysosomal glycogen
General function
Short descriptionAvalglucosidase alfa is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Avalglucosidase alfa is a recombinant human acid α-glucosidase (rhGAA) that provides an exogenous source of GAA. Avalglucosidase alfa is a modification of alglucosidase alfa in which approximately 7 hexamannose structures each containing 2 terminal mannose-6-phosphate (bis-M6P) moieties are conjugated to oxidized sialic acid residues on alglucosidase alfa. Avalglucosidase alfa has a 15-fold increase in mannose-6-phosphate (M6P) moieties compared with alglucosidase alfa. Binding to M6P receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalised and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity to degrade glycogen.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Avalglucosidase alfa is a recombinant alpha-glucosidase (GAA) enzyme that catalyzes hydrolysis of glycogen. In clinical trials, avalglucosidase alfa reduced the levels of glycogen excreted in the urine of patients with Pompe disease, indicating that it effectively cleaved excess glycogen. Avalglucosidase alfa has significantly higher binding affinity for cation-independent mannose-6-phosphate receptor (CI-MPR) for cellular uptake and better muscle targeting than alglucosidase alfa. In GAA-deficient mice, avalglucosidase alfa reduced glycogen with more efficacy than alglucosidase alfa at an equivalent dose.
Original license holder
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Marketing authorisation numbers
EU/1/21/1579/001-4
Marketing authorisation holder
Sanofi B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands
Name of the manufacturer of the biological active substance
Genzyme Flanders
Cipalstraat 8
2440 Geel, Belgium
Name and address of the manufacturer(s) responsible for batch releaseGenzyme Ireland Limited,
IDA Industrial Park,
Old Kilmeaden Road,
Waterford, Ireland
Max shelf life
4 years
Storage conditions
2°C – 8°C
List of excipients
Histidine
Histidine hydrochloride monohydrate
Glycine
Mannitol
Polysorbate 80

Support

Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.

How the ordering process works:

1 – Create your wishlist by adding the molecules you need.

2 – Export your wishlist as a PDF or send it to Evidentic.

3 – Receive a non-binding quote within 24 hours.

Frequently asked questions​

At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.

Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.

If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.

But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.

And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.

Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!

Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like:

  • Use as reference molecules for your assays
  • In functional in-vitro assays
  • For analytical procedures
  • For biosimilar and new drug early development
  • To compare against your research-grade molecules

Looking for a specific molecule?

Have a question?

Thank you for your interest in our services.

We will respond to you within one working day. You can now download your sample report.